Campaigners meet in Singapore to raise awareness and funds for Parkinson’s disease
In benefit of Parkinson Society Singapore, Project Novo, a service learning group from the Hwa Chong Institution, is hosting its inaugural ‘Run for Parkinson’s’ event. The run will be held on 13 August at the Piai Plaza, Pasir Ris Park, Singapore.
The fundraiser, which offers both a 5km and 8km course, is open to everyone, with campaigners being encouraged to walk and run at their own pace.
The main aims of the event are to raise both awareness and vital funds for the Parkinson’s community in Singapore. The proceeds from the run will be donated to The Parkinson’s Centre, who will use them to support therapeutic programmes for the local Parkinson’s community.
The Parkinson Society Singapore also hope to highlight how people living with Parkinson’s can manage their condition through exercise. Including exercise as part of a daily routine can improve mobility in joints as well as reduce stress and anxiety.
After the run, there will be a variety of activities and booths set up to help those attending better understand the condition.
Parkinson Society Singapore
The Parkinson Society Singapore was established in 1996 by a group of medical professionals and care givers who wished to help those with Parkinson’s. In Singapore around 4,000 people currently live with the condition, however this figure is expected to rise due to an ageing population.
The event is free for people with Parkinson’s, pre-registration is required here
Take the Parkinson’s Life survey for a chance to win!
Parkinson’s Life 2016 Survey: tell us what you think
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.